Oncolytic adenoviruses (Ads) have potential applications in cancer therapy due to their ability to replicate and induce tumor cell death. However, their clinical application has been limited by the lack of efficient cell-based delivery systems that can provide protection from immune attack and prevent virus clearance by neutralizing antibodies. We previously demonstrated that menstrual blood-derived mesenchymal stem cells (MenSCs) can specifically target tumor cells and serve as a novel drug delivery platform. We engineered CRAd5/F11 chimeric oncolytic Ads that can infect MenSCs and preserve their tumor targeting ability in vitro. MenSCs loaded with these Ads were transplanted in a mouse tumor model. We found that a large number of the CRAd5/F11 viruses were accumulated in tumor site and mediated marked inhibitory effects against colorectal cancer (CRC). Thus, we concluded that MenSC-cloaked oncolytic Ads hold great potential as a novel virus-delivery platform for the therapy of various cancers, including CRC.
Get full access to this article
View all access options for this article.
References
1.
InoueY, IshidaH, UenoH, KobayashiH, YamaguchiT, KonishiT, TomitaN, MatsubaraN, IshidaF, et al. (2016). Therapeutic approaches for patients with coexisting familial adenomatous polyposis and colorectal cancer. Jpn J Clin Oncol, 46:819–824.
2.
FerlayJ, SoerjomataramI, DikshitR, EserS, MathersC, RebeloM, ParkinDM, FormanD and BrayF. (2015). Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer, 136:E359–E386.
3.
EdwardsBK, NooneAM, MariottoAB, SimardEP, BoscoeFP, HenleySJ, JemalA, ChoH, AndersonRN, et al. (2014). Annual Report to the Nation on the status of cancer, 1975–2010, featuring prevalence of comorbidity and impact on survival among persons with lung, colorectal, breast, or prostate cancer. Cancer, 120:1290–1314.
4.
CattaneoR, MiestT, ShashkovaEV and BarryMA. (2008). Reprogrammed viruses as cancer therapeutics: targeted, armed and shielded. Nat Rev Microbiol, 6:529–540.
5.
FukuharaH, InoY and TodoT. (2016). Oncolytic virus therapy: a new era of cancer treatment at dawn. Cancer Sci, 107:1373–1379.
6.
MorenoR, RojasLA, VillellasFV, SorianoVC, Garcia-CastroJ, FajardoCA and AlemanyR. (2017). Human menstrual blood-derived mesenchymal stem cells as potential cell carriers for oncolytic adenovirus. Stem Cells Int, 2017:3615729.
7.
LarsonC, OronskyB, ScicinskiJ, FangerGR, StirnM, OronskyA and ReidTR. (2015). Going viral: a review of replication-selective oncolytic adenoviruses. Oncotarget, 6:19976–19989.
8.
WoldWS and TothK. (2013). Adenovirus vectors for gene therapy, vaccination and cancer gene therapy. Curr Gene Ther, 13:421–433.
9.
NiemannJ and KuhnelF. (2017). Oncolytic viruses: adenoviruses. Virus Genes, 53:700–706.
YamamotoY, NagasatoM, YoshidaT and AokiK. (2017). Recent advances in genetic modification of adenovirus vectors for cancer treatment. Cancer Sci, 108:831–837.
12.
YeGJ, ConlonT, ErgerK, SonnentagP, SharmaAK, HowardK, KnopDR and ChulayJD. (2015). Safety and biodistribution evaluation of rAAV2tYF-CB-hRS1, a recombinant adeno-associated virus vector expressing retinoschisin, in RS1-deficient mice. Hum Gene Ther Clin Dev, 26:177–184.
13.
Vishnu VardhanGP, SavithriHS, MurthyMR and HemaM. (2016). Biodistribution and toxicity evaluation of sesbania mosaic virus nanoparticles in mice. Arch Virol, 161:2673–2681.
14.
BruckmanMA, RandolphLN, VanMeterA, HernS, ShoffstallAJ, TaurogRE and SteinmetzNF. (2014). Biodistribution, pharmacokinetics, and blood compatibility of native and PEGylated tobacco mosaic virus nano-rods and -spheres in mice. Virology, 449:163–173.
15.
HassanF, LossieSL, KasikEP, ChannonAM, NiS and KennedyMA. (2018). A mouse model study of toxicity and biodistribution of a replication defective adenovirus serotype 5 virus with its genome engineered to contain a decoy hyper binding site to sequester and suppress oncogenic HMGA1 as a new cancer treatment therapy. PLoS One, 13:e0192882.
16.
ShiM, ZhangZ, XuR, LinH, FuJ, ZouZ, ZhangA, ShiJ, ChenL, et al. (2012). Human mesenchymal stem cell transfusion is safe and improves liver function in acute-on-chronic liver failure patients. Stem Cells Transl Med, 1:725–731.
17.
MaderEK, ButlerG, DowdySC, MarianiA, KnutsonKL, FederspielMJ, RussellSJ, GalanisE, DietzAB and PengKW. (2013). Optimizing patient derived mesenchymal stem cells as virus carriers for a phase I clinical trial in ovarian cancer. J Transl Med, 11:20.
18.
PatelMR and KratzkeRA. (2013). Oncolytic virus therapy for cancer: the first wave of translational clinical trials. Transl Res, 161:355–364.
19.
ChaurasiyaS and WarnerS. (2017). Viroimmunotherapy for colorectal cancer: clinical studies. Biomedicines, 5:pii: E11.
20.
WorkenheST and MossmanKL. (2014). Oncolytic virotherapy and immunogenic cancer cell death: sharpening the sword for improved cancer treatment strategies. Mol Ther, 22:251–256.
21.
TakanashiK, DanK, KanzakiS, HasegawaH, WatanabeK and OgawaK. (2017). The preventive effect of the traditional Japanese herbal medicine, Hochuekkito, against influenza A virus via autophagy in vitro. Pharmacology, 99:99–105.
22.
DingDC, ChangYH, ShyuWC and LinSZ. (2015). Human umbilical cord mesenchymal stem cells: a new era for stem cell therapy. Cell Transplant, 24:339–347.
23.
OgguGS, SasikumarS, ReddyN, EllaKKR, RaoCM and BokaraKK. (2017). Gene delivery approaches for mesenchymal stem cell therapy: strategies to increase efficiency and specificity. Stem Cell Rev, 13:725–740.
24.
KazimirskyG, JiangW, SlavinS, Ziv-AvA and BrodieC. (2016). Mesenchymal stem cells enhance the oncolytic effect of Newcastle disease virus in glioma cells and glioma stem cells via the secretion of TRAIL. Stem Cell Res Ther, 7:149.
25.
LingX, MariniF, KonoplevaM, SchoberW, ShiY, BurksJ, Clise-DwyerK, WangRY, ZhangW, et al. (2010). Mesenchymal stem cells overexpressing IFN-beta inhibit breast cancer growth and metastases through stat3 signaling in a syngeneic tumor model. Cancer Microenviron, 3:83–95.
26.
MaderEK, MaeyamaY, LinY, ButlerGW, RussellHM, GalanisE, RussellSJ, DietzAB and PengKW. (2009). Mesenchymal stem cell carriers protect oncolytic measles viruses from antibody neutralization in an orthotopic ovarian cancer therapy model. Clin Cancer Res, 15:7246–7255.
27.
GuoY, ChenB, ChenLJ, ZhangCF and XiangC. (2016). Current status and future prospects of mesenchymal stem cell therapy for liver fibrosis. J Zhejiang Univ Sci B, 17:831–841.
28.
CampagnoliC, RobertsIA, KumarS, BennettPR, BellantuonoI and FiskNM. (2001). Identification of mesenchymal stem/progenitor cells in human first-trimester fetal blood, liver, and bone marrow. Blood, 98:2396–2402.
29.
De UgarteDA, MorizonoK, ElbarbaryA, AlfonsoZ, ZukPA, ZhuM, DragooJL, AshjianP, ThomasB, et al. (2003). Comparison of multi-lineage cells from human adipose tissue and bone marrow. Cells Tissues Organs, 174:101–109.
EricesA, CongetP and MinguellJJ. (2000). Mesenchymal progenitor cells in human umbilical cord blood. Br J Haematol, 109:235–242.
32.
JiangYH, VaessenaB, LenvikT, BlackstadM, ReyesM and VerfaillieCM. (2002). Multipotent progenitor cells can be isolated from postnatal murine bone marrow, muscle, and brain. Exp Hematol, 30:896–904.
RossignoliF, CaselliA, GrisendiG, PiccinnoS, BurnsJS, MurgiaA, VeronesiE, LoschiP, MasiniC, et al. (2013). Isolation, characterization, and transduction of endometrial decidual tissue multipotent mesenchymal stromal/stem cells from menstrual blood. Biomed Res Int, 2013:901821.
36.
ChenL, ZhangC, ChenL, WangX, XiangB, WuX, GuoY, MouX, YuanL, et al. (2017). Human menstrual blood-derived stem cells ameliorate liver fibrosis in mice by targeting hepatic stellate cells via paracrine mediators. Stem Cells Transl Med, 6:272–284.
37.
WuX, LuoY, ChenJ, PanR, XiangB, DuX, XiangL, ShaoJ and XiangC. (2014). Transplantation of human menstrual blood progenitor cells improves hyperglycemia by promoting endogenous progenitor differentiation in type 1 diabetic mice. Stem Cells Dev, 23:1245–1257.
38.
Alcayaga-MirandaF, CuencaJ, Luz-CrawfordP, Aguila-DiazC, FernandezA, FigueroaFE and KhouryM. (2015). Characterization of menstrual stem cells: angiogenic effect, migration and hematopoietic stem cell support in comparison with bone marrow mesenchymal stem cells. Stem Cell Res Ther, 6:32.
39.
CaoW, TianJ, LiC, GaoY, LiuX, LuJ, WangY, WangZ, SvatekRS and RodriguezR. (2017). A novel bladder cancer—specific oncolytic adenovirus by CD46 and its effect combined with cisplatin against cancer cells of CAR negative expression. Virol J, 14:149.
40.
BolontradeMF, SgangaL, PiaggioE, VialeDL, SorrentinoMA, RobinsonA, SevleverG, GarciaMG, MazzoliniG and PodhajcerOL. (2012). A specific subpopulation of mesenchymal stromal cell carriers overrides melanoma resistance to an oncolytic adenovirus. Stem Cells Dev, 21:2689–2702.
41.
GaggarA, ShayakhmetovDM and LieberA. (2003). CD46 is a cellular receptor for group B adenoviruses. Nat Med, 9:1408–1412.
42.
TylerMA, UlasovIV, SonabendAM, NandiS, HanY, MarlerS, RothJ and LesniakMS. (2009). Neural stem cells target intracranial glioma to deliver an oncolytic adenovirus in vivo. Gene Ther, 16:262–278.
43.
De BoeckA, PauwelsP, HensenK, RummensJL, WestbroekW, HendrixA, MaynardD, DenysH, LambeinK, et al. (2013). Bone marrow-derived mesenchymal stem cells promote colorectal cancer progression through paracrine neuregulin 1/HER3 signalling. Gut, 62:550–560.
44.
ZhangX, HuF, LiG, LiG, YangX, LiuL, ZhangR, ZhangB and FengY. (2018). Human colorectal cancer-derived mesenchymal stem cells promote colorectal cancer progression through IL-6/JAK2/STAT3 signaling. Cell Death Dis, 9:25.
45.
BlenmanKR and LeePP. (2014). Quantitative and spatial image analysis of tumor and draining lymph nodes using immunohistochemistry and high-resolution multispectral imaging to predict metastasis. Methods Mol Biol, 1102:601–621.
46.
AminKM. (2003). Ad5 and Ad3 chimeric fiber travels into the cell without the CAR. Cancer Biol Ther, 2:516–517.
47.
WangZ, WangY, YangT, LiJ and YangX. (2017). Study of the reparative effects of menstrual-derived stem cells on premature ovarian failure in mice. Stem Cell Res Ther, 8:11.
48.
RodriguesMC, LippertT, NguyenH, KaelberS, SanbergPR and BorlonganCV. (2016). Menstrual blood-derived stem cells: in vitro and in vivo characterization of functional effects. Adv Exp Med Biol, 951:111–121.
49.
Le BlancK, FrassoniF, BallL, LocatelliF, RoelofsH, LewisI, LaninoE, SundbergB, BernardoME, et al. (2008). Mesenchymal stem cells for treatment of steroid-resistant, severe, acute graft-versus-host disease: a phase II study. Lancet, 371:1579–1586.
50.
NiessH, von EinemJC, ThomasMN, MichlM, AngeleMK, HussR, GuntherC, NelsonPJ, BrunsCJ and HeinemannV. (2015). Treatment of advanced gastrointestinal tumors with genetically modified autologous mesenchymal stromal cells (TREAT-ME1): study protocol of a phase I/II clinical trial. BMC Cancer, 15:237.
51.
WuKH, TsaiC, WuHP, SieberM, PengCT and ChaoYH. (2013). Human application of ex vivo expanded umbilical cord-derived mesenchymal stem cells: enhance hematopoiesis after cord blood transplantation. Cell Transplant, 22:2041–2051.
52.
DoceulV, HollinsheadM, van der LindenL and SmithGL. (2010). Repulsion of superinfecting virions: a mechanism for rapid virus spread. Science, 327:873–876.
53.
CeccarelliS, ViscoV, RaffaS, WakisakaN, PaganoJS and TorrisiMR. (2007). Epstein-Barr virus latent membrane protein 1 promotes concentration in multivesicular bodies of fibroblast growth factor 2 and its release through exosomes. Int J Cancer, 121:1494–1506.
54.
GiuglianoS, KrissM, Golden-MasonL, DobrinskikhE, StoneAE, Soto-GutierrezA, MitchellA, KhetaniSR, YamaneD, et al. (2015). Hepatitis C virus infection induces autocrine interferon signaling by human liver endothelial cells and release of exosomes, which inhibits viral replication. Gastroenterology, 148:392–402 e13.
55.
NagashimaS, JirintaiS, TakahashiM, KobayashiT, Tanggis, NishizawaT, KoukiT, YashiroT and OkamotoH. (2014). Hepatitis E virus egress depends on the exosomal pathway, with secretory exosomes derived from multivesicular bodies. J Gen Virol, 95:2166–2175.
56.
WeiT, HibinoH and OmuraT. (2009). Release of Rice dwarf virus from insect vector cells involves secretory exosomes derived from multivesicular bodies. Commun Integr Biol, 2:324–326.
57.
FergusonSW, WangJ, LeeCJ, LiuM, NeelameghamS, CantyJM and NguyenJ. (2018). The microRNA regulatory landscape of MSC-derived exosomes: a systems view. Sci Rep, 8:1419.
58.
LouGH, ChenZ, ZhengM and LiuYN. (2017). Mesenchymal stem cell-derived exosomes as a new therapeutic strategy for liver diseases. Experimental and Molecular Medicine. 49.
59.
BlissSA, SinhaG, SandifordOA, WilliamsLM, EngelberthDJ, GuiroK, IsenalumheLL, GrecoSJ, AyerS, et al. (2016). Mesenchymal stem cell-derived exosomes stimulate cycling quiescence and early breast cancer dormancy in bone marrow. Cancer Res, 76:5832–5844.
60.
NongKT, WangWW, NiuX, HuB, MaCC, BaiYQ, WuB, WangY and AiKX. (2016). Hepatoprotective effect of exosomes from human-induced pluripotent stem cell-derived mesenchymal stromal cells against hepatic ischemia-reperfusion injury in rats. Cytotherapy, 18:1548–1559.
61.
PhinneyDG and PittengerMF. (2017). Concise review: MSC-derived exosomes for cell-free therapy. Stem Cells, 35:851–858.
62.
SimsB, GuL, KrendelchtchikovA and MatthewsQL. (2014). Neural stem cell-derived exosomes mediate viral entry. Int J Nanomedicine, 9:4893–4897.
63.
RakiM, SarkiojaM, EscutenaireS, KangasniemiL, HaavistoE, KanervaA, CerulloV, JoensuuT, OksanenM, PesonenS and HemminkiA. (2011). Switching the fiber knob of oncolytic adenoviruses to avoid neutralizing antibodies in human cancer patients. J Gene Med, 13:253–261.
64.
RussellSJ, PengKW and BellJC. (2012). Oncolytic virotherapy. Nat Biotechnol, 30:658–670.
65.
CupelliK, MullerS, PerssonBD, JostM, ArnbergN and StehleT. (2010). Structure of adenovirus type 21 knob in complex with CD46 reveals key differences in receptor contacts among species B adenoviruses. J Virol, 84:3189–3200.
66.
YuL, TakenobuH, ShimozatoO, KawamuraK, NimuraY, SekiN, UzawaK, TanzawaH, ShimadaH, OchiaiT and TagawaM. (2005). Increased infectivity of adenovirus type 5 bearing type 11 or type 35 fibers to human esophageal and oral carcinoma cells. Oncol Rep, 14:831–835.
67.
LimB, AllenJE, PrabhuVV, TalekarMK, FinnbergNK and El-DeiryWS. (2015). Targeting TRAIL in the treatment of cancer: new developments. Expert Opin Ther Targets, 19:1171–1185.
68.
TrivediR and MishraDP. (2015). Trailing TRAIL resistance: novel targets for TRAIL sensitization in cancer cells. Front Oncol, 5:69.
69.
FuldaS and VucicD. (2012). Targeting IAP proteins for therapeutic intervention in cancer. Nat Rev Drug Discov, 11:109–124.
70.
SunD, ZhaoL, LinJ, ZhaoY and ZhengY. (2018). Cationic liposome co-encapsulation of SMAC mimetic and zVAD using a novel lipid bilayer fusion loaded with MLKL-pDNA for tumour inhibition in vivo. J Drug Target, 26:45–54.
Supplementary Material
Please find the following supplemental material available below.
For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.
For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.
